A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance
AC Huang, R Zappasodi - Nature immunology, 2022 - nature.com
Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …
Identification of neoantigens for individualized therapeutic cancer vaccines
Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …
recognized by autologous T cells in the host. As neoepitopes are not subject to central …
Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers
The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge
for the engineering of cell-based cancer immunotherapies. By mapping 55 neoantigen …
for the engineering of cell-based cancer immunotherapies. By mapping 55 neoantigen …
A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy
The strategy of combining a vaccine with immune checkpoint inhibitors has been widely
investigated in cancer management, but the complete response rate for this strategy is still …
investigated in cancer management, but the complete response rate for this strategy is still …
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results
Checkpoint inhibitor (CPI) therapies provide limited benefit to patients with tumors of low
immune reactivity. T cell-inducing vaccines hold promise to exert long-lasting disease …
immune reactivity. T cell-inducing vaccines hold promise to exert long-lasting disease …
Mechanisms of immune activation and regulation: lessons from melanoma
Melanoma, a skin cancer that develops from pigment cells, has been studied intensively,
particularly in terms of the immune response to tumours, and has been used as a model for …
particularly in terms of the immune response to tumours, and has been used as a model for …
Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
Adoptive T cell therapy (ACT) using ex vivo–expanded autologous tumor-infiltrating
lymphocytes (TILs) can mediate complete regression of certain human cancers. The impact …
lymphocytes (TILs) can mediate complete regression of certain human cancers. The impact …
A review of cancer immunotherapy: from the past, to the present, to the future
K Esfahani, L Roudaia, N Buhlaiga, SV Del Rincon… - Current …, 2020 - mdpi.com
A review of cancer immunotherapy: from the past, to the present, to the future Page 1 S87
Current Oncology, Vol. 27, Supp. 2, April 2020 © 2020 Multimed Inc. REVIEW ARTICLE A …
Current Oncology, Vol. 27, Supp. 2, April 2020 © 2020 Multimed Inc. REVIEW ARTICLE A …
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy
C Puig-Saus, B Sennino, S Peng, CL Wang, Z Pan… - Nature, 2023 - nature.com
Neoantigens are peptides derived from non-synonymous mutations presented by human
leukocyte antigens (HLAs), which are recognized by antitumour T cells,,,,,,,,,,,,–. The large …
leukocyte antigens (HLAs), which are recognized by antitumour T cells,,,,,,,,,,,,–. The large …
MHC-II neoantigens shape tumour immunity and response to immunotherapy
E Alspach, DM Lussier, AP Miceli, I Kizhvatov… - Nature, 2019 - nature.com
The ability of the immune system to eliminate and shape the immunogenicity of tumours
defines the process of cancer immunoediting. Immunotherapies such as those that target …
defines the process of cancer immunoediting. Immunotherapies such as those that target …